Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2

Ähnliche Einträge

• Glucose-6-phosphate dehydrogenase deficiency and SARS-CoV-2 mortality: Is there a link and what should we do?
  von: Nabavi, Seyed Fazel, et al.
  Veröffentlicht: (2020)
• Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2
  von: Habtemariam, Solomon, et al.
  Veröffentlicht: (2020)
• Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?
  von: Habtemariam, Solomon, et al.
  Veröffentlicht: (2020)
• Rationale for Effective Prophylaxis Against COVID‐19 Through Simultaneous Blockade of Both Endosomal and Non‐Endosomal SARS‐CoV‐2 Entry into Host Cell
  von: Nabavi, Seyed Fazel, et al.
  Veröffentlicht: (2021)
• Lessons from SARS and MERS remind us of the possible therapeutic effects of implementing a siRNA strategy to target COVID‐19: Shoot the messenger!
  von: Habtemariam, Solomon, et al.
  Veröffentlicht: (2020)